论文部分内容阅读
哈药集团是集科、工、贸为一体的大型企业,现拥有1个控股上市子公司、13个全资子公司。20a5年7月23日,哈药集团发布公告称,公司控股股东哈药集团有限公司转为中外合资企业,已经获得商务部批复。企业性质变更后,哈药集团有限公司的注册资本为37亿元。2005年10月底,哈药集团发布公
Harbin Pharmaceutical Group is set by the Branch, engineering, trade as one of the large enterprises, now has a holding subsidiary listed, 13 wholly owned subsidiaries. On July 23, 2005, Harbin Pharmaceutical Group issued a public notice that converting its controlling shareholder, Harbin Pharmaceutical Group Co., Ltd. into a Sino-foreign joint venture, has received the approval of the Ministry of Commerce. After the change of enterprise nature, Harbin Pharmaceutical Group Co., Ltd. registered capital of 3.7 billion yuan. By the end of October 2005, Harbin Pharmaceutical Group issued a public